Tech Company Financing Transactions
XNK Therapeutics Funding Round
On 10/9/2023, XNK Therapeutics announced $155 thousand in investment from Vinnova.
Transaction Overview
Company Name
Announced On
10/9/2023
Transaction Type
Venture Equity
Amount
$155,000
Round
Undisclosed
Investors
Vinnova (Lead Investor)
Proceeds Purpose
The company is at the forefront of autologous NK cell-based cell therapy development with a proprietary technology platform and a pipeline spanning both hematological malignancies and solid tumor indications.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Hälsovägen 7 Novum
Huddinge, 141 57
SE
Huddinge, 141 57
SE
Phone
Undisclosed
Website
Email Address
Overview
XNK Therapeutics is a clinical-stage biotechnology company developing unique and individualized natural killer (NK) cell-based cancer therapies. The R&D pipeline targets areas of high unmet medical need within both hematological malignancies and solid tumors. The most advanced product candidate, evencaleucel, is being evaluated in a phase II clinical study in combination with the CD38 monoclonal antibody isatuximab, as consolidation therapy following stem cell transplantation in newly diagnosed multiple myeloma patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Johan Liwing
Chief Financial Officer
Hugo Petit
Chief Medical Officer
Peter Hovstadius
Chief Scientific Officer
Anna Maltais
Browse more venture capital transactions:
Prev: 10/9/2023: Varm venture capital transaction
Next: 10/9/2023: 0xScope venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are derived from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs